Alpharma
This article was originally published in The Tan Sheet
Executive Summary
Company will ship generic Cromolyn Sodium Nasal Solution USP to several major drugstores in the first half of August, firm says. Alpharma received final approval of ANDA 74-800 for its Nasalcrom equivalent July 26 and is second private labeler to receive FDA clearance; Bausch & Lomb's generic cromolyn sodium was approved in early July (1"The Tan Sheet" July 9, p. 28). Pharmacia's Nasalcrom lost marketing exclusivity July 3, 2000 after receiving six months of pediatric exclusivity
You may also be interested in...
Pfizer BenaMist Launch Delayed By Manufacturing Issues
Pfizer Consumer Healthcare's launch of its BenaMist Allergy Prevention Nasal Spray is being delayed due to production problems faced by contract manufacturer Alpharma, Pfizer said
Generic cromolyn sodium
Bausch & Lomb receives FDA clearance for private label OTC nasal solution July 3. B&L's application (ANDA 75-702) appears to be first approved by agency for generic equivalent to Pharmacia's NasalCrom, which lost marketing protection July 3, 2000 after receiving six months of pediatric exclusivity. Perrigo said it will introduce a cromolyn sodium product this year. In late March, Pharmacia received approval of a new age indication for NasalCrom, allowing for use in children ages two to five (1"The Tan Sheet" April 9, p. 11)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC